key: cord-0897105-mxqtei5e
authors: Mursi, Ali M; Mirghani, Hyder O; Elbeialy, Adel A
title: A Case Report of Post COVID19 Giant Cell Arteritis and Polymyalgia Rheumatica With Visual Loss
date: 2022-03-21
journal: Clin Med Insights Case Rep
DOI: 10.1177/11795476221088472
sha: 4b752d57f0e5267c0c3f863ea9d76283cee2eec8
doc_id: 897105
cord_uid: mxqtei5e

COVID-19 shares some features of giant-cell arteritis, in which the diagnosis needs a high suspicion for prompt investigation and therapy. When the diseases coexist this might lead to diagnosis delay with grave consequences. We reported a case of a post-COVID-19 giant cell arteritis and polymyalgia rheumatica with visual loss. We treated the patient with pulse methylprednisolone 1 gm daily for 3 consecutive days followed by 60 mg prednisolone for 4 weeks until normalization of ESR, and then, gradual withdrawal. Oral Paracetamol, vitamin-D3, and calcium carbonate were added to the treatment regimen. The headache continued, so, we started perineural injection therapy (PIT) once daily, for 6 sessions, at which the headache was completely resolved after the third injection. The vision was regained completely after the sixth injection.

Giant-cell arteritis (GCA) overlaps polymyalgia rheumatic (PMR) in about 21%, 1 and usually among those ⩾50 years. Polymyalgia rheumatica should be considered in patients with acute onset of bilateral upper extremity pain worsening with or after rest. It is prudent to early recognize giant-cell arteritis and initiate glucocorticoid therapy to avoid ischemic optic neuropathy and permanent loss of vision. 2 COVID-19 is known for its immune dysregulation. Interleukins were found to have a strong association with rheumatic diseases during the COVID-19 pandemic. For instance, interleukin-6 and interleukin-17 showed association with giant-cell arteritis and arthritis among those infected with COVID-19. 3 COVID-19 patients with large vessel vasculitis showed a higher rate of fatality and hospitalization and Tocilizumab and glucocorticoids were shown to improve the outcomes. 4 Systemic vasculitis was the fourth most common rheumatic disease among patients hospitalized for COVID-19, with poor and irreversible clinical outcomes due to delay in diagnosis of AAV during the COVID-19 pandemic. 5 Many researchers reported COVID-19 triggering systemic vasculitis, polymyalgia rheumatica, and giant-cell arteritis, with variable and largely unmodifiable risk factors. [6] [7] [8] We reported a case of GCA associated with PMR in a patient with COVID-19.

A 61-years old female with type 2 diabetes mellitus, hypertension (BP 180/100 mmHg), dyslipidemia (cholesterol 289 mg/dl, triglycerides 195 mg/dl), and hypothyroidism presented with recent onset left temporal continuous headache; the history started 45 days before. The patient gave a history of hospitalization 2 months ago, for 10 days because of PCR-confirmed COVID-19 infection. On examination, the patient looked ill; the vital signs were within normal. She had bilateral shoulder and limb-girdle stiffness, jaw claudication, and weight loss. In addition, she had a visual loss of the left eye and blurring of vision in the right eye, for which she was prescribed topical treatment by an ophthalmologist. Temporal artery biopsy showed 

Clinical Medicine Insights: Case Reports recanalization after inflammation (Figure 1 ). Investigations were: ESR = 73 mm, CRP = 60 mg/l, WBCs = 18.400 × 10 9 cell/l with 92% neutrophils, hemoglobin = 11.3 gm/l, platelets = 288 000 c/mcl, rheumatoid factor (RF), and antinuclear antibodies (ANA) were negative. IgG antibodies for covid-19, Epstein-Barr (EBV) were detected, while bacteriological screening was negative. Echocardiography, MRA, CT Angiogram for aorta and its major branches were normal, which excluded aortitis.

As the patient fulfilled The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis, 9 diagnoses were settled as giant cell arteritis with polymyalgia rheumatica.

The patient was on Telmisartan 40 mg daily, Verapamil 80 mg daily, Metformin 500 mg/8 hourly, Rusovastatin 10 mg once daily, and Levothyroxine 50 mg once daily.

We added to the regimen pulse methylprednisolone 1 gm daily for 3 consecutive days followed by 60 mg prednisolone for 4 weeks until normalization of ESR, followed by gradual withdrawal. Oral Paracetamol, vitamin-D3, and calcium carbonate were added to the treatment regimen. The headache continued, so, we started perineural injection therapy (PIT) once daily, for 6 sessions, at which the headache was completely resolved after the third injection. The vision was regained completely after the sixth injection.

Perineural injection therapy (PIT) consists of a series of small injections immediately under the skin targeting painful areas where the sensocrine nerves are sensitive, with simple and natural substances. The substance is a buffered D5W (dextrose 5% in sterile water) with a neutral pH of 7.4. 10-13

We reported a case of post-COVID-19 giant-cell arteritis. Similarly, Jonathan et al 14 presented a case of post-COVID-19-and Giant Cell Arteritis-Like Vasculitis. High suspicion and early diagnosis are of primary importance to avoid permanent vision loss as observed in our case. Studies from Italy observed higher visual loss from GCA during the COVID-19 outbreak. 14 Interestingly, presentation with otalgia and visual loss were reported with normal ESR in cases that showed positive COVID-19. 15 Literature from several parts of the world observed the association of COVID-19 and giant-cell arteritis. [16] [17] [18] Therefore, it is wise to suspect GCA in those over 50 years of age presenting with symptoms in one or both eyes, or persistent frontal or parietal headache (Table 1) . A high rate of suspicion, prompt investigation, and treatment promptly are vital to avoid permanent vision loss. 19 

Epidemiology of polymyalgia rheumatica in Olmsted County

Polymyalgia rheumatica and giant cell arteritis

Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?

A guide to immunotherapy for COVID-19

Giant cell arteritis, and COVID-19: similarities and discriminators. A systematic literature review

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19

Global Rheumatology Alliance physician registry: a retrospective cohort study

Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity'. Ann Rheum Dis

SARS-CoV-2 infection triggering a giant cell arteritis

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis

Explanation of prolotherapy and perineural injection therapy (Perineural subcutaneous injection and perineural deep injection)

Pain Management by Prolotherapy and Perineural Injection Therapy: Non-Surgical Interventional Regenerative Orthopedic Medicine

Perineural injection therapy in the management of complex regional pain syndrome: a sweet solution to pain

Effectiveness of perineural injections combined with standard postoperative total knee arthroplasty protocols in the management of chronic postsurgical pain after total knee arthroplasty

A case of post-COVID-19-associated paracentral acute middle maculopathy and giant cell arteritis-like vasculitis

Increased number of cases of giant cell arteritis and higher rates of ophthalmic involvement during the era of COVID-19

Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis

Thinking beyond giant cell arteritis in COVID-19 times

Giant cell arteritis during COVID-19 pandemic

Giant cell arteritis: early diagnosis is key

All authors contributed equally in examining, diagnosing, and treating the patient. They also contributed to writing and revising the manuscript, while Professor Adel Elbeialy is the corresponding and responsible author.

Ali M Mursi https://orcid.org/0000-0002-5034-8545